Agree - positive clinical trial data is what we need. And there should be plenty of that in the coming months across our 4 clinical trials. Starting with the CDH17 CAR-T GI cancer trial, where the CEO said during a media interview in December that the company was waiting on FDA approval to publish prelim data on the first 3 patients...so this could happen any day now.
We are also eligible for FDA Orphan Drug Designations across all our assets. So that could happen at any time....
Similarly, with some positive data, we will also be eligible for fast track / breakthrough or regenerative medicine FDA designations across all our assets. This could also happen in the near term!
Add to My Watchlist
What is My Watchlist?
